Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer

Clinical trial NCT07476677 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07476677
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Prostate Cancer

Start date: 2026-04-01
Primary completion: 2027-12-31
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.